ArticleFrontiers in oncology2026
Noninvasive assessment of core metastatic genes in lung adenocarcinoma: development of a predictive model integrating single-cell transcriptomics and radiomics.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) leads to death primarily due to its high metastatic potential. Risk assessment methodologies currently predicated on histopathological and imaging features possess a limited capacity to predict metastatic potential. Therefore, integrating single-cell transcriptomics and CT radiomics to identify key molecular drivers of metastasis and establishing a noninvasive imaging prediction model for LUAD is important. Methods: Bulk transcriptomic data and single-cell RNA sequencing (scRNA-seq) data were obtained from public database for analysis. Analytical tools (Seurat, inferCNV, Monocle, WGCNA, LASSO regression, GO/KEGG/GSEA, CellChat) were used for cellular profiling, trajectory analysis, gene identification, functional enrichment, and cell-cell communication. Immunohistochemistry (IHC) and RT-qPCR validated candidate genes at protein and mRNA levels. Additionally, a CT radiomics-based predictive model was developed for noninvasive gene expression assessment. Results: ScRNA-seq analysis revealed a malignant cellular trajectory from primary to metastatic LUAD and identified a metastasis-associated subpopulation. Three consistently overexpressed genes (PSMB5, PSMB7 and SLC16A3) were correlated with poor prognosis. Functional studies indicated their synergistic roles in promoting tumor progression through cell cycle regulation, proteasome activity, and metabolic reprogramming. A CT radiomics model effectively predicted the combined expression of these genes (AUC = 0.765), linking imaging features to molecular phenotypes. Conclusion: This study reveals that the synergistic expression pattern of PSMB5, PSMB7 and SLC16A3 is closely associated with lung adenocarcinoma metastasis and poor prognosis, confirming their potential value as prognostic biomarkers and therapeutic targets. The CT radiomics model offers a noninvasive tool for molecular phenotyping, aiding in preoperative precision assessment and advancing noninvasive clinical decision-making for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.